Evidence-based deprescribing of proton pump inhibitors in long-term care
Date
2018
Authors
Sluggett, J.
Hendrix, I.
Bell, J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Research in Social and Administrative Pharmacy, 2018; 14(2):124-126
Statement of Responsibility
Conference Name
Abstract
In a recent issue of Research in Social and Administrative Pharmacy,Rane et al. reported 27% of nursing home residents in the United States in 2004 took a proton pump inhibitor (PPI), and only half of these residents had an appropriate indication.1 One of the strengths of this study was the use of a large, nationally representative data source to assess PPI use. The high prevalence of PPI use demonstrated by Rane et al. and other studies conducted in the long-term care setting is concerning.1e6 Although PPIs are generally well tolerated, and are thought to have a low incidence of serious adverse drug events (ADEs), older residents of long term care facilities (LTCFs) may be particularly susceptible.7 Pneumonia,clostridium difficile infection and fractures are leading causes of hospitalization among residents of LTCFs. The high prevalence of PPI use in this setting means that even low-incidence ADEs can impact a large number of residents. Minor ADEs, suchas gastrointestinal upset and headache, can have considerableimpact on quality of life among residents of LTCFs.3
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
Copyright 2017 Elsevier